4'-N-(tert-butoxycarbonyl-L-leucyl)primaquine | 737004-38-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4'-N-(tert-butoxycarbonyl-L-leucyl)primaquine
• 英文别名: (S)-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-4-methyl-1-oxopropan-2-ylcarbamic acid tert-butyl ester；N-{7-[(6-methoxyquinolin-8-yl)amino]-3-aza-1-isobutyl-2-oxooctyl}carbamic acid tert-butyl ester；Boc-Leu-primaquine
• CAS: 737004-38-5
• 化学式: C₂₆H₄₀N₄O₄
• 分子量: 472.628
• InChiKey: YMFINNGLTJWYCQ-YSYXNDDBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.88
• 重原子数：
  34.0
• 可旋转键数：
  11.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  101.58
• 氢给体数：
  3.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  4'-N-(tert-butoxycarbonyl-L-leucyl)primaquine 在 palladium on activated charcoal N-甲基吗啉 、 盐酸 、 氢气 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 4-[4-[[(2S,3S)-1-[[(3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]phenoxy]-N-[(2S)-1-[[(2S)-1-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]benzamide
  参考文献：
  名称：

  High Antiplasmodial Activity of Novel Plasmepsins I and II Inhibitors

  摘要：

  The aim of this study was to develop new antiplasmodial compounds acting through distinct mechanisms during both the liver and the blood stages of the parasite life cycle. Compounds were designed on the basis of the "double-drug" approach: primaquine, which has been linked to statine-based inhibitors of plasmepsins (PLMs), the plasmodial aspartic proteases involved in degradation of hemeoglobin. The compounds were tested in vitro for anti-PLM I/PLM II activities and against chloroquine-sensitive (D10) and chloroquine-resistant (W2) strains of P. falciparum. An antiplasmodial activity (IC50) as low as 0.1 mu M was obtained, an excellent improvement in comparison with inhibitors previously reported (IC50 = 2 - 20 mu M). The killing activity was equally directed against both P. falciparum strains and was correlated to lipophilicity (calculated as ALogP), for all compounds but one (9). All compounds inhibited PLM I and PLM II in the nanomolar range (K-i = 1 - 700 nM). The most promising compounds (2, 6, 10) were not cytotoxic against human fibroblasts at 100 mu M and were highly selective for PLMs vs human cathepsin D.

  DOI：

  10.1021/jm061033d
• 作为产物：
  描述：

  BOC-L-亮氨酸 、 伯氨喹 在 1-羟基苯并三唑 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 4'-N-(tert-butoxycarbonyl-L-leucyl)primaquine
  参考文献：
  名称：

  在N端带有一个咪唑啉丁-4-酮部分的伯氨喹二肽衍生物作为潜在的抗疟原药

  摘要：

  合成了在N-末端带有咪唑烷基-4-酮部分的伯氨喹二肽衍生物，并将其评估为潜在的阻断传导的抗疟原药。所有化合物均在中性和碱性溶液中水解为伯氨喹的母体二肽衍生物，其半衰期在37°C下为0.7至31 h，具体取决于咪唑烷酮-4-one部分和烷基中存在的取代基的性质。 C端氨基酸直接偶联至伯氨喹。使用由伯氏疟原虫，BalbC小鼠和按蚊按蚊组成的模型研究了所选化合物的抗疟活性蚊子。由丙氨酸-丙氨酸伯氨喹和丙酮衍生的咪唑啉丁-4-酮比伯氨喹更有效地减少了感染向蚊子的传播，这表现为蚊子中肠中的卵囊数量显着减少，分别为10和50μmol/与对照相比，kg。

  DOI：

  10.1016/j.ejmech.2009.01.018

文献信息

• Biodegradable Microspheres. 16. Synthesis of Primaquine–Peptide Spacers for Lysosomal Release from Starch Microparticles
  作者：Rossitsa Borissova、Bernard Lammek、Peter Stjärnkvist、Ingvar Sjöholm

  DOI：10.1002/jps.2600840226

  日期：1995.2

  tetrapeptide spacer arm for the rate of lysosomal enzymatic release of PQ can be possible. A third group, comprising epsilon-aminocaproic acid-PQ derivatives which lack a free alpha-amino group, was synthesized. This was done to study the importance of enzymes, other than aminopeptidases, during lysosomal degradation of these derivatives. To allow HPLC analysis of the pattern of degradation of tetrapeptide-PQ

  采用经典的肽合成方法合成了四组化合物，并为每组化合物开发了分析方法。其中两个是抗衰老药物伯氨喹（PQ）的四肽衍生物，其一般结构为NH2-X-Leu-Ala-Y-PQ。第一组，Y位置使用Leu，Tyr，Lys和Asp，而X为Ala；第二组，X位置使用Ala，Tyr，Lys和Asp在X位置，Y为Leu。这些衍生物旨在通过其游离的α-氨基与聚丙烯酸酯淀粉微粒（在我们实验室开发的溶同溶性药物载体）偶联。因此，对PQ的溶酶体酶促释放速率的四肽间隔臂的不同氨基酸组成的重要性的系统研究是可能的。第三组 合成了包含缺少游离α-氨基的ε-氨基己酸-PQ衍生物的化合物。这样做是为了研究在这些衍生物的溶酶体降解过程中除氨肽酶以外的酶的重要性。为了允许HPLC分析四肽-PQ衍生物的降解模式，还制备了一些较短的肽-PQ衍生物（第四组）。
• Synthesis of imidazolidin-4-one and 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-dione derivatives of primaquine: scope and limitations
  作者：Paula Gomes、Maria João Araújo、Manuela Rodrigues、Nuno Vale、Zélia Azevedo、Jim Iley、Paula Chambel、José Morais、Rui Moreira

  DOI：10.1016/j.tet.2004.04.077

  日期：2004.6

  The synthesis of imidazolidin-4-one derivatives of primaquine as potential antimalarial agents is described. The target compounds were synthesized in three steps: (i) condensation of (±)-primaquine with Nα-protected amino acids, (ii) removal of the Nα-protecting group, and (iii) reaction of the N-acylprimaquine with a carbonyl compound: acetone, three cyclic ketones and veratraldehyde. Using 2-formylbenzoic

  描述了伯氨喹的咪唑啉丁-4-酮衍生物作为潜在的抗疟药的合成。在三个步骤中合成的目标化合物：（ⅰ）的缩合（±）-primaquine用N α -保护的氨基酸，（ⅱ）除去N-的α保护基团，和（iii）的N acylprimaquine与反应羰基化合物：丙酮，三个环酮和藜芦醛。在得到第三步骤，使用2-甲酰基苯甲酸1 H ^ -咪唑并[2,1-一个]异吲哚-2,5（3 ħ，9B ħ） -二酮。分离出的所有产物均具有良好的收率。咪唑啉丁-4-酮是所有可能的非对映异构体的等量混合物，而1 H-咪唑并[2,1-以立体选择性的方式产生]异吲哚-2,5（3 H，9b H）-二酮。化合物在pH 7.4缓冲液中水解非常缓慢（t 1/2 5–30 d），释放出伯氨喹。这些伯氨喹衍生物正在接受生物学检测，其抗疟活性的初步结果令人鼓舞。
• Biodegradable Microspheres VI: Lysosomal Release of Covalently Bound Antiparasitic Drugs from Starch Microparticles
  作者：Timo Laakso、Peter Stjärnkvist、Ingvar Sjöholm

  DOI：10.1002/jps.2600760210

  日期：1987.2

  The possibilities of using polyacryl starch microparticles as a carrier for low molecular weight drugs have been investigated. Two drugs containing primary amino groups, primaquine and trimethoprim, have been covalently coupled to the starch microparticles via tri-, tetra-, and pentapeptide spacer arms. The drug-particle complexes were prepared by coupling different drug-peptide derivatives to the

  已经研究了使用聚丙烯酸酯淀粉微粒作为低分子量药物的载体的可能性。含有伯氨基的两种药物伯氨喹和甲氧苄氨嘧啶已经通过三肽，四肽和五肽间隔臂与淀粉微粒共价偶联。通过用羰基二咪唑活化淀粉后，将不同的药物-肽衍生物偶联到颗粒上来制备药物-颗粒复合物。随后除去活化基团的活化过程没有改变淀粉微粒的降解性。所得的药物-载体复合物在血清中稳定，而游离药物以溶酶体级分释放。因此，微粒-肽-药物结合物满足了用于将药物靶向溶酶体的药物载体的基本要求（例如，
• Anti-Pneumocystis carinii and antiplasmodial activities of primaquine-derived imidazolidin-4-ones
  作者：Nuno Vale、Margaret S. Collins、Jiri Gut、Ricardo Ferraz、Philip J. Rosenthal、Melanie T. Cushion、Rui Moreira、Paula Gomes

  DOI：10.1016/j.bmcl.2007.11.105

  日期：2008.1

  A series of primaquine-derived imidazolidin-4-ones were screened for their in vitro activity against Pneumocystis carinii and Plasmodium falciparum W2 strain. Most compounds were active against P. carinii above 10 mu g/mL and displayed slight to marked activity. The imidazolidin-4-ones most active against P. carinii were also those most active antiplasmodial agents, in the mu M range. One of the tested imidazolidin-4-ones was slightly more active than the parent primaquine and may represent a lead compound for the development of novel anti-P. carinii 8-aminoquinolines with increased stability and resistance to metabolic inactivation. (c) 2007 Elsevier Ltd. All rights reserved.